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Abstract
Background: This study investigated the molecular characteristics of azithromycin-resistant Streptococcus pneumoniae
in Taiwan.
Methods: A total of 486 non-duplicate isolates of azithromycin-resistant S. pneumoniae recovered from various clinical
sources of patients treated at 22 different hospitals in Taiwan from 2006 to 2010. The presence of erm(B) and mef(A)
genes using duplex PCR, multilocus sequence typing (MLST), and pulsed-field gel electrophoresis of these isolates were
studied.
Results: Of the isolates tested, 59% carried the erm(B) gene, 22% carried the mef(A) gene, and 19% carried both genes.
The prevalence of isolates carrying the erm(B) and mef(A) genes increased from 10% (11/110) in 2006 to 25% (15/60) in
2010 (p-value = 0.0136). The majority of isolates carrying both erm(B) and mef(A) genes belonged to serotypes 19 F
(64%) followed by 19 F A (24%). Of these isolates, 33% were sequence type 320 (ST320), 32% were ST236, and 12%
were ST271.
Conclusions: The increase in incidence of mef(A)/erm(B)-positive azithromycin-resistant S. pneumoniae isolates during
the study period was primarily due to serotypes 19 F and 19A and ST236 and ST320.
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Background
Streptococcus pneumoniae is a leading cause of bacterial
pneumonia, meningitis, and sepsis worldwide. Since 1965,
many cases of infections due to drug-resistant S. pneumo-
niae have been reported [1]. The emergence of antimicro-
bial resistance is correlated with selective pressure from the
use, often inappropriate, of antimicrobial agents and results
in increased mortality, morbidity, and health care costs [2].
Antibacterial resistance in S. pneumoniae is increasing, af-
fecting principally β-lactams and macrolides (azithromycin,
erythromycin, or clarithromycin) with prevalence ranging
between 1% and 90% depending on the geographical area
[3]. Fluoroquinolone resistance has also been reported in
countries with high levels of antibacterial resistance and
consumption [3].
Macrolide resistance in S. pneumoniae is most often
mediated by two mechanisms: target-site modification
encoded by the erm(B) gene and active drug efflux medi-
ated by a membrane efflux pump encoded by mef-class
genes [4]. Song et al. reported the erm(B) gene was found
in >50% of pneumococcal isolates either alone or in com-
bination with mef(A) among S. pneumoniae isolates from
10 Asian countries during 1998 2001 [5]. In Finland and
Germany, the most frequent macrolide resistance deter-
minant carried was the mef gene [6,7]. Macrolide resist-
ance among pneumococcal isolates in Alaska recovered
from 1986 2010 was also reported to be predominantly
mediated by mef genes and this has not changed signifi-
cantly over time [8]. However, the authors of the study re-
ported a significant increase in the proportion of isolates
that possess both erm(B) and mef(A), primarily among
serotype 19A isolates.
* Correspondence: hsporen@ntu.edu.tw
2Department of Internal Medicine, National Taiwan University Hospital,
National Taiwan University College of Medicine, Taipei, Taiwan
4Department of Laboratory Medicine, National Taiwan University Hospital,
National Taiwan University College of Medicine, Taipei, Taiwan
Full list of author information is available at the end of the article
2014 Safari et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Safari et al. BMC Infectious Diseases 2014, 14:704
http://www.biomedcentral.com/1471-2334/14/704
Bowers et al. reported that of 592 clinical pneumococ-
cal isolates collected in Arizona from 1999 to 2008, all
isolates carrying the erythromycin-resistant genes mef(E)
and erm(B) were multidrug-resistant clonal lineages of
Taiwan 19 F-14 and most were multilocus sequence type
(ST) 320 [9]. In China, recent studies have shown that
erythromycin-resistant isolates commonly carry both genes
and that the majority of isolates belong to ST271, ST320,
ST236, with clonal complex 271 (CC271) being the most
frequently isolated CC [10-12]. In 2005, two predominant
macrolide-resistant S. pneumoniae CCs, namely CC271
and CC15, were identified in New South Wales, Australia
[13]. Recently, Tsai et al. reported the prevalence of sero-
type 19A pneumococcal isolates increased significantly in
Taiwan from 2006 to 2010 and that more than 90% of the
isolates were non-susceptible to azithromycin [14]. In the
current study, we investigated the molecular characteristics
of azithromycin-resistant S. pneumoniae recovered from
various clinical sources of patients who were treated at 22
different hospitals in Taiwan from 2006 to 2010.
Methods
Bacterial isolates
A total of 530 consecutive and non-duplicate pneumococ-
cal isolates were collected from various clinical specimens
of patients treated at 22 different hospitals in Taiwan dur-
ing a 3-month period per year, with a maximum number
of isolates per year of 10 during 2006 2008 and 5 during
2009 2010 [14]. Among these isolates, 486 were not
susceptible to azithromycin [14]. These pneumococcal
isolates were collected as part of the Tigecycline In Vitro
Surveillance in Taiwan (TIST) study, a nationwide, multi-
center, prospective surveillance study conducted in 12 re-
gional hospitals (500 1000 beds) and 10 medical centers
(1200 3000 beds) (eight in northern, four in central, six
in southern and two in eastern Taiwan) from January
2006 to December 2010 [15], Pneumococcal isolates were
identified at each hospital and the identification was con-
firmed by the central laboratory at the National Taiwan
University Hospital [15]. Serotype determination by a latex
agglutination method and antimicrobial susceptibility test-
ing by the broth microdilution method were performed as
described previously [14]. Isolates were collected as part
of standard patient care and no ethical approval required
for your use.
Detection of erm(B) and mef(A) genes
The detection of erm(B) and mef(A) was performed by
duplex PCR as previously described [5,16].
Pulsed-field gel electrophoresis (PFGE) analysis
PFGE analysis of isolates was performed as described
previously [17,18]. The Dice coefficient of similarity was
calculated and the unweighted pair group method with
arithmetic averages (UPGMA) was used for cluster ana-
lysis. Isolates with coefficients of similarity ≥80% were con-
sidered to be the same cluster [18].
Multilocus sequence typing (MLST)
MLST was performed as described previously [19]. Al-
lele profiles and sequence types were determined using
the MLST database (http://spneumoniae.mlst.net/).
Statistical analysis
Statistical analyses were conducted using GraphPad
Prism V5.0 (GraphPad Software, San Diego, CA, USA).
Results
Prevalence of isolates carrying the erm(B) and mef(A)
genes
Among the 486 isolates, 59% carried the erm(B) gene,
22% carried the mef(A) gene, and 19% carried both genes
(Table 1). The prevalence of isolates carrying the erm(B)
gene did not differ significantly from year to year (p-value =
0.2436) (Table 1); the prevalence of isolates carrying the
mef(A) gene declined significantly from 30% in 2006 to 5%
in 2010 (p-value = 0.0001); and the prevalence of isolates
carrying both genes increased significantly from 10% in
2006 to 25% in 2010 (p-value = 0.0136) (Table 1). There
were no obvious geographic differences with respect to
the distribution of isolates carrying erm(B), mef(A), or both
genes (data not shown).
Table 1 Prevalence of erm(B) and mef(A) genes among azithromycin-resistant Streptococcus pneumoniae isolates from
22 hospitals in Taiwan from 2006 to 2010
Resistant gene No. (%) of isolates, by study period Total (n = 486)
2006 2007 2008 2009 2010
(n = 110) (n = 110) (n = 153) (n = 53) (n = 60)
erm(B)-positive 66 (60) 65 (59) 92 (60) 24 (45) 42 (70) 289 (59)
mef(A)-positive 33 (30) 26 (24) 33 (22) 11 (21) 3 (5) 106 (22)
mef(A)/erm(B)-positive 11 (10) 19 (17) 28 (18) 18 (34) 15 (25) 91 (19)
P-value* - 0.1683 0.8716 0.0224 0.3091
*P-value for temporal change of mef(A)/erm(B)-positive by study period.
Safari et al. BMC Infectious Diseases 2014, 14:704 Page 2 of 6
http://www.biomedcentral.com/1471-2334/14/704
Serotype and sequence type of isolates carrying both
erm(B) and mef(A) genes
All isolates of serotype 3 and 15B carried only erm(B)
(Table 2). The majority of the other main serotypes also
carried only the erm(B) gene, namely serotype 23 F (73%),
14 (87%), 23A (86%), and 6B (54%) (Table 2). Among sero-
type 19 F isolates, 13% carried the erm(B) gene, 36% car-
ried the mef(A) gene, and 52% carried both genes. The
majority of serotype 19A isolates carried both erm(B) and
mef(A) genes (61%) (Table 2). Of 91 these isolates carried
both genes, 58 (64%) of isolates were belong to serotype
19 F, followed by 19A (22/91; 24%).
The distribution of isolates harboring erm(B) and mef(A)
genes by sequence type was 33% for ST320, 32% for
ST236, 12% for ST271, 8% for ST81, 2% for ST283 and
ST8525, and 11% for other sequence types (Table 3). The
majority of ST236 (28/29) and ST271 (10/11) clones
belonged to serotype 19 F. Isolates of clone ST320 mainly
belonged to serotype 19 F (16/30) and serotype 19A (13/30)
(Table 3). Seven isolates of clone ST81 were identified as
belonging to serotype 23 F (n = 2), 23A (n = 1) and 6A
(n = 4). Based on the results of MLST allelic profiling, the
ST236 and ST81 clones were identified as reference strain
of PMEN global clone Taiwan19F-14 and reference strain
of PMEN global clone Spain23F-1 respectively (Table 3).
ST320 and ST271 clones were identified as a double-
locus variant (DLV) and a single-locus variant (SLV) of
the worldwide-established Taiwan19F-14 (ST236) clone
respectively.
Clusters of isolates carrying both erm(B) and mef(A) genes
We constructed a phylogenetic tree based on PFGE pro-
files and found no specific clustering for the strains of
serotype 19 F and 19A or for the three major sequence
types (ST320, ST271, and ST236) (Figure 1). In this
study, the isolates carrying both erm(B) and mef(A) were
stratified into eight clusters (Cluster I to VIII) by PFGE
(Figure 1 and Table 4). Clusters III, IV, V, and VII corre-
sponded to the isolates with serotype 19 F (Table 4). Iso-
lates belonging to the same cluster can have different
serotypes and STs. Furthermore, several isolates with the
same ST also exhibited different serotypes and pulsotypes.
The majority of isolates of serotype 19A were in cluster VI
(13/24, 54%). ST320 clone isolates belonged to cluster VI
(13/24, 54%), cluster II (9/16, 56%), and cluster I (2/4,
50%). Meanwhile, isolates of clone ST236 were frequently
clustered in cluster V (9/9, 100%) and III (6/7, 86%)
(Table 4). The majority of ST81 clone isolates were clus-
tered in cluster VIII (4/5, 80%).
Discussion
Azithromycin is the most commonly used macrolide in
the treatment of community-acquired pneumonia and
other respiratory tract infections in Taiwan. The rate of
susceptibility to azithromycin remained stationary from
2006 to 2010 in Taiwan, although the numbers of iso-
lates randomly collected in 2009 and 2010 were lower
than in 2006 to 2008 [14]. In Taiwan, PCV-7 vaccination
was introduced in October 2005 and PCV-13 was intro-
duced in July 2010. Nevertheless, some studies have
shown that changes in antimicrobial susceptibility before
and after implementation of the PCV-7 vaccine were not
associated with serotypes [14]. Our finding of increase in
the rate of azithromycin-resistant S. pneumoniae isolates
carrying the erm(B) and mef(A) genes from from 10%
in 2006 to 25% in 2010 after the introduction of the
Table 2 Correlation between the main serotypes of











19F 112 14 (13) 40 (36) 58 (52)
23 F 90 66 (73) 21 (23) 3 (3)
14 71 62 (87) 8 (11) 1 (1)
6B 66 35 (53) 29 (44) 2 (3)
19A 36 10 (28) 4 (11) 22 (61)
3 23 23 (100) 0 (0) 0 (0)
15B 15 15 (100) 0 (0) 0 (0)
23A 16 14 (88) 1 (6) 1 (6)
NT 28 25 (89) 3 (11) 0 (0)
Others** 29 25 (86) 0 (0) 4 (14)
NT: nontypeable.
*Data of serotype were used in this study as reported by Tsai HY et al. [14],
**Include 9 V (n = 9), 6A (n = 9), 10A (n = 2), 20 (n = 1), 11A (n = 1), 15A (n = 5),
22 F (n = 2).
Table 3 Sequence type and Serotype of azithromycin-
resistant Streptococcus pneumoniae isolates with PCR







236 29 (32) 19 F (28), 19A (1) Taiwan19F-14/ST236
320 30 (33) 19F (16), 19A (13),
14 (1)
DLV of Taiwan19F-14/ST236
271 11 (12) 19 F (10), 19A (1) SLV of Taiwan19F-14/ST236
81 7 (8) 23 F (2), 23A (1),
6A (4)
Spain23F-1/ST81
283 2 (2) 19 F (2) -
8525 2 (2) 19 F (2) -
Others* 10 (11) 19 F (4), 19A (3),
23 F (1), 6B (2)
-
ST: Sequence type; PMEN: Pneumococcal molecular epidemiology network.
*Others (n): ST3111 (1), ST3164 (1), ST6993 (1), ST7123 (1), ST237 (1), ST257 (1),
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Figure 1 A phylogenetic tree analysis based on pulsed-field gel electrophoresis profiles with SmaI among isolates of azithromycin-resistant
Streptococcus pneumoniae carrying both erm(B)/mef(A) genes.
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pneumococcal conjugate vaccine in Taiwan. These find-
ings are in line with a previously published report on the
PROTEKT US surveillance study from 10% in 2000 1 to
16% in 2003 [21], the study in Alaska from 0% in 1986 to
21% in 2010 [8], and the study in Canada from 3% in 1998
to 19% in 2008 [22].
In this study, the majority of azithromycin-resistant
isolates carrying both mef(A) and erm(B) genes was sero-
type 19 F (58/91; 64%), followed by19A (22/91; 24%) and
is similar to a previous published report in Korea, 57%
of carried both genes were serotype 19 F (44/77, 57%),
followed by 19A (21/77, 30%)7.5%) [23]. However, the
study in Alaska showed 79% of isolates carrying both
genes was serotype 19A (15/19), followed by 19 F (3/19;
16%) [8].
We investigated further via MLST and PFGE all iso-
lates carried both the erm(B) and mef(A), and identified
33% of these to be of ST320, followed by ST236 (32%),
ST271 (12%), and other STs (23%). Previously, it was
reported in Taiwan that the CCs related to Spain23F-1,
Taiwan19F-14, and Taiwan23F-15 were responsible for the
spread of isolates with high-beta-lactam resistance [24,25].
Recently, the S. pneumoniae serotype 19A ST320 clone,
derived from an international Taiwan19F-14 (ST236)
clone, has become prevalent in many countries, in-
cluding Taiwan [25]. In Arizona, the isolates carrying
both mef(E)/erm(B)-positive genes are multidrug-resistant
clonal lineages of Taiwan19F-14 [9].
In the last two decades, PFGE and MLST have become
the main genotyping methods for assessing the genetic
diversity of isolates [26]. Although both methods are time-
and labor-consuming, they are useful for studying the
local and global epidemiology of S. pneumoniae. In the
present study, discrepancies of typing results by these two
methods occurred. Since pneumococci are capable of
undergoing capsular switching and are recognized as one
of the most recombinogenic bacteria, additional typing
methods, i.e. multiple-locus variable number tandem re-
peat analysis and MILST, have been developed recently to
offer better discrimination in S. pneumoniae isolates [26].
Conclusions
The increase in incidence of mef(A)- and erm(B)-positive
azithromycin-resistant S. pneumoniae isolates during
the study period was primarily due to serotypes 19 F and
19A and ST236 and ST320.
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Table 4 Pulsed-field gel electrophoresis (PFGE) clusters, serotypes and sequence types of azithromycin-resistant
Streptococcus pneumoniae isolates with PCR positive for erm(B)/mef(A)-positive genes
PFGE cluster* No. of isolates (n = 87)** Serotype (no. of isolates) Sequence type (no. of isolates)
I 4 19 F (3), 19A (1) 320 (2), 236 (2)
II 16 19 F (12), 19A (4) 320 (9), 236 (2), 271 (5)
III 7 19 F (7) 236 (6), 271 (1)
IV 3 19 F (3) 320 (1), 236 (1), 237 (1)
V 9 19 F (9) 236 (9),
VI 24 19 F (11), 19A (13) 320 (13), 236 (3), 271 (3), 6993 (1) 3164 (1),
7123 (1), 8525 (1), 283 (1),
VII 4 19 F (4) 320 (1), 236 (1), 271 (1), 283 (1)
VIII 5 19 F (1), 6A (2), 23 F (1), 23A (1), 236 (1), 81 (4)
Un-clustered 15 19 F (7), 19A (3), 23 F (2), 6B (1), 6A (1), 14 (1) 320 (3), 236 (4), 271 (1), 81 (2), 76 (1), 275 (1),
2993 (1), 3111 (1), 3625 (1)
*PFGE-based clusters were defined as groups of 3 or more isolates with ≥80% similarity on the dendrogram.
**PFGE data were not available for four isolates (H03-020-2010, H04-004-2008, H12-017-2009, H15-012-2008).
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